
“WHAT I cannot create, I do not understand.” Last week, 25 leading synthetic biologists decided it was time to follow Richard Feynman’s famous credo.
After nearly two decades spent poring over the 3 billion letters or base pairs that make up the human genome, they announced a 10-year plan to chemically synthesise one. “Reading the genome can only get you so far. At some point you have to build it,” says Susan Rosser of the Mammalian Synthetic Biology Research Centre at the University of Edinburgh, UK, and a co-author on the paper outlining the plan.
The team, which counts among its leaders the maverick geneticist George Church, says it is aiming to launch the ambitious initiative this year, depending on raising an initial £100 million.
Advertisement
“You could use this plain yogurt of humanity to slot in different genes and find out what they do“
The primary goal of the Human Genome Project-Write, as it is known, is to engineer large genomes of up to 100 billion base pairs, including “whole genome engineering of human cell lines and other organisms of agricultural and public health significance”, the team writes. This will require technological development early on in the project “to propel large-scale genome design and engineering” (Science, ).
The artificial genome won’t be derived from any one person, but will be created using computer-aided design – one of the main players is software company Autodesk. Chunks of synthetic DNA could then be put into cell lines, like those used to test drugs, or into E.coli bacteria, the workhorse of the research lab, with the host genetic material gradually being replaced.
While difficult to put a figure on the cost at this stage, the team says it expects the final bill to be less than the $3-billion cost of the first Human Genome Project.
But what’s the point of such a lofty proposal? To entice funders, the team has outlined several pilot projects that will take advantage of the progress as it is made. Those discussed in the paper include the development of an ultra-safe line of cells that would be virus resistant, cancer resistant and free of potentially harmful genes that could lead, for example, to prion diseases.
That would be a boon for stem cell medicine, says Paul Freemont, who runs the synthetic biology centre at Imperial College London. One of the benefits of stem-cell therapies is that the cells can multiply rapidly – but this is also a characteristic shared by cancer cells, so a therapeutic injection of stem cells turning cancerous has long been a concern. “A synthetic biology variant encoded to never become cancerous would be preferable,” he says.
Other projects include finding the minimal human genome – the tiniest possible stash of DNA capable of supporting life – and adapting the pig genome so it becomes a better source of organs for human transplants.
There’s also a proposal to develop a reference human genome. This would consist of the most common gene variants that humans carry at every single position of the genome. It could be used to make a cell that has a generalised genome that most accurately represents the baseline genetic code of the majority of the human race.
Church calls the genome this would create a totally plain human. “If you had this, you can introduce variants of unknown significance one at a time. These are turning up constantly in genome research but you don’t know if the variants are causal, or how many it takes [to cause disease],” he says. “You could use this blank slate, this plain yogurt of humanity, to slot in the different genes and find out”.
This could help identify why some populations are more susceptible to certain diseases, for example sickle cell anaemia, which is more common in people of African, African American or Mediterranean heritage. “This would be a way of finding out why,” says Freemont.
Some see darker applications, however. “Some of the speculative goals of this project sound innocuous or benign… Others would be dangerously unacceptable,” said Marcy Darnovsky, who heads the California-based Center for Genetics and Society, in a statement. In an interview with US radio station NPR, she said: “The worry is that – manufacturing chromosomes that could be used ultimately to produce synthetic human beings that they see as improved models.”
“The worry is that it could be used to produce synthetic humans they see as improved models“
While there is no suggestion that the artificial DNA sequence created by the project would be put into a human egg or embryo, allowing the creation of a human from scratch, the paper doesn’t do much to allay these fears. While it mentions ethical considerations, it doesn’t state clearly what potential risks or ethical quandaries the project might raise, says Baojun Wang, also at the University of Edinburgh. More justifiable reasons than those given in the paper – namely that it would deliver important scientific advances and reduce the cost of genetic engineering – are needed to start the HGP-Write project, he says. “The investment is huge and long-term and will involve governmental taxpayers money.”
Francis Collins, director of the US National Institutes of Health, agrees. “NIH has not considered the time to be right for funding a large-scale production-oriented ‘HGP-Write’ effort,” he said in a statement.
Then there’s the question of who would own the synthesised genome. Unlike existing DNA that has been manipulated, a wholly synthetic cell could be owned outright. This could benefit any corporations involved. “If you process it in your lab, it is yours, you can patent it,” says Laurie Zoloth, a bioethicist at Northwestern University in Evanston, Illinois.
Genome owner
“In the first Human Genome Project, it was clear that the knowledge gained would be owned by everyone – anyone can download and use the information,” says Freemont. “But it’s less clear how that will work with this project – this will not be digital information, this will be a physical entity… It’s an issue that hasn’t been sorted out.”
Rosser says that is exactly the discussion the team’s paper is intended to catalyse.
But not everyone is placated by the authors’ talk of “responsible innovation”. Zoloth and Drew Endy, a synthetic biologist at Stanford University, say the authors fail to pose essential questions in their proposal. “Nor do they detail specific limits about what should not be done.” This raises the question of whether the group is well equipped to organise and lead such a project, the pair say.
Church says that people are working to make sure certain actions cannot be carried out. As an example, he points to the now widely implemented safety standards he devised in 2004 to .
What is certain is that there is still plenty of time to get things in order. With just a few groups capable of writing genomes with millions of bases, the synthetic human is a long way off.
An almighty leap
The project to create an artificial human genome will build on previous work to construct synthetic genomes
Rewriting baker’s yeast
Sc2.0 is an international attempt to , Saccharomyces cerevisiae, one of the first organisms to be sequenced.
The yeast genome is tiny: just 12 million base pairs on 16 chromosomes, compared with the 3 billion base pairs of the human genome spread over 23 chromosomes. The project should address some previously unanswerable questions, such as how transposons – “jumping genes” that insert themselves in DNA – evolve. The project is expected to finish in 2018.
Craig Venter’s artificial bacteria
In 2010, a team led by Craig Venter reported that it had synthesised the only chromosome of the bacterium Mycoplasma mycoides and transplanted it into an empty chassis of a separate strain of Mycoplasma.
Earlier this year, the team announced that it had whittled down the 901 genes of the synthetic bacterium to the minimum needed to support life. Of these essential genes, we have no idea what 31 per cent of them do.
Uncertain ambition
The Human Genome Project–Write was generating controversy before it was even officially announced.
On 10 May, team members held an invitation-only meeting at Harvard University. Attendees were barred from speaking with the press, leaving people to guess at the applications of the rumoured project. This led to “.
The reality will be less sensational but just as radical, says geneticist George Church at Harvard, one of the leaders of the project. “We are not well suited to 60-mile commutes, a super-abundance of food, and certainly not for being astronauts,” says Church. Knowledge gleaned from this project could, for example, switch off the genes that make us susceptible to type 2 diabetes.
While the descriptions of the applications (see main story) seem uncontroversial enough, greater ambitions may lurk behind them. “There has been a ratcheting down of the rhetoric of the project [since 10 May],” says Hank Greely of the Stanford Centre for Law and the Biosciences. “But whether there’s been a ratcheting down of the plans, I don’t know”.
Clues may lie in its leaders’ wider interests. During presentations, for example, Church likes to show a slide on which .
Andrew Hessel of software company Autodesk, who , is a Singularity University, which explicitly tries to adapt to a future in which technology outpaces biology. Hessel has often into an accessible “programming language”, using Autodesk software.
This article appeared in print under the headline “Synthetic humans are go”